Current and future perspectives in diagnostic imaging as a guide to targeted/local therapies in breast cancer recurrence

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 4, 2013, Pages 367-380

  Evangelista, L ^a   Mezzato, C ^b   Felloni, G ^b   Saladini, G ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Breast neoplasms; Neoplasm recurrence, local; Tomography, x ray computed

Indexed keywords

CETUXIMAB; DASATINIB; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; LAPATINIB; TACROLIMUS; TRASTUZUMAB;

BRAIN METASTASIS; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; ELECTROCHEMOTHERAPY; HUMAN; NEUTRON CAPTURE THERAPY; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT PLANNING;

EID: 84891593023     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Le M, Arriagada R, Spielmann M, Guinebrietiere J-M, Rochard F. Prognostic factors for death an isolated local recurrence in patients with early-stage breast carcinoma. Cancer 2002;94:2813-20. (Pubitemid 34547678)
2. Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and withou radiotherapy: results from five National A Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol 2004;22:4247-54. (Pubitemid 41185145)
3. Singletary SE, Walsh G, Vauthey JN, Curley S, Sawaya R, Weber KL et al. A role for curative surgery in the treatment of selected patients with metastastic breast cancer. Oncologist 1994;8:241-51.
4. Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009;27:1585-91.
5. Macdermed DM, Weichselbaum R, Salama JK. A rationale for the targeted treatement of oligometastases with radiotherapy. J Surg Oncol 2008;98:202-6.
6. Solin LJ, Harris EE, Orel SG, Glick J. Local-regional recurrence after breast conserving treatment or matsectomy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Disease of the breast. 3rd ed. Philapelphia, PA: Lippincott Williams & Wilkins; 2004.
7. Aukema TS, Rutgers E, Vogel WV, Teertstra HJ, Oldenburg HS, Vranken Peeters MTFD et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques. Eur J Surg Oncol 2010;36:387-92.
8. Dirisamer A, Halpern BS, Flory D, Wolf F, Beheshti M, Mayerhoefer ME, Langsteger W. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. Eur J Radiol 2010;73:294-9.
9. Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. Amer J Radiol 2004;183:479-86. (Pubitemid 38970344)
10. Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW. [18F]-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003;129:147-53. (Pubitemid 36583695)
11. Radan L, Ben-Haim S, Bar-Shalom R, Gurainink L, Israel O. The Role of FDG-PET/CT in Suspected Recurrence of Breast Cancer. Cancer 2006;107:2545-51. (Pubitemid 44845606)
12. Suga K, Kawakami Y, Hiyama A, Matsunaga N. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan. Ann Nucl Med 2009;23:399-407.
13. Veit-Haibach P, Antoch G, Beyer T, Stergar H, Schleucher R, Hauth EAM et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Brit J Radiol 2007;80:508-15. (Pubitemid 47343078)
14. Evangelista L, Baretta Z, Vinante L, Bezzon E, De Carolis V, Cervino AR et al. Comparison of 18F-FDG positron emission tomography/computed tomography in patients with already-treated breast cancer: diagnostic and prognostic implications. Q J Nucl Med Mol Imaging 2012;56:375-84.
15. Veronesi U, De Cicco C, Galimberti VE. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007;18:473-8. (Pubitemid 46359625)
16. Manohar K MB, Senthil R, Kashyap R, Bhattacharya A, Singh G. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Nuc Med Comm 2012;33:591-6.
17. Schneider-Kolsky ME, Hart S, Fox J, Midolo P, Stuckey J, Hofman M, Ganju V. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res 2010;R37:1-11.
18. Ohsumi S, Inoue T, Kiyoto S, Hara F, Takahashi M, Takabatake D et al. Detection of isolated ipsilateral regional lymph node recurrences by F18-fluorodeoxyglucose positron emission tomography - CT in follow-up of postoperative breast cancer patients. Breast Cancer Res Treat 2011;130:267-72.
19. Redana S, De Carolis V, Racca M, Zago C, Varetto T, Montemurro F et al. Descriptive analysis of the management of breast cancer patients with a solitary lesion diagnosed with 18-fluorodeoxyglucose positron emission tomography/computed tomography scan. Cancer Res 2011;71(24 Suppl):244s.
20. Delanian S, Lefaix J. Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. Semin Radiat Oncol 2007;17:99-107. (Pubitemid 46476864)
21. Wurshmidt F, Dahle J, Petersen C, Wenzel C, Kretschmer M, Bastian C. Reirradiation of recurrent breast cancer with and without concurrent chemotherapy. Radiation Oncol 2008;3:28-37.
22. Chua SC, Ashley M, Irfan K, Menez L, Svetislav G, Du Y et al. The impact of 18F-FDG-PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 2007;34:1906-14. (Pubitemid 350212127)
23. Huguet EL, Old S, Praseedom RK, Balan KK, Gibbs P, Jamieson NV. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases. Hepatogastroenterology 2007;54:1667-71. (Pubitemid 350068450)
24. Akriviadis EA, Llovet JM, Efremidis SC, Shouval D, Canelo R, Ringe B, Meyers WC. Hepatocellular carcinoma. Br J Surg 1998;85.
25. Desai DC, Zervos EE, Arnold MW, Burak WE Jr, Mantil J, Martin EW Jr. Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol 2003;10:59-64.
26. Rydzewski B, Dehadashti F, Gordon BA, Teefey SA, Strasberg SM, Siegel BA. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. AJR Am J Roentgenol 2002;178:353-8. (Pubitemid 34098037)
27. Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G et al. The use of 18F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008;35:1323-9.
28. Solbiati L, Ierace T, Tonolini M, Osti V, Cova L. Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound 2001;13:149-58. (Pubitemid 32463284)
29. Blokhius TJ, van der Schaaf MC, van den Tol MP, Comans EFI, Manoliu RA, van der Sijp JRM. Results of Radio Frequency Ablation of Primary and Secondary Liver Tumors: Long-term Follow-up with Computed Tomography and Positron Emission Tomography-18F-deoxyfluoroglucose Scanning. Scand J Gastroenterol Suppl 2004;241:93-7. (Pubitemid 40051456)
30. Travaini LL, Trifirò G, Ravasi L, Monfardini L, Della Vigna P, Bonomo G, Chiappa A et al. Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging 2008;35:1316-22.
31. Donkier V, van Laethetm JL, Goldman S, van Gansbeke D, Feron P, Ickx B et al. [F-18] Fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003;84:215-23. (Pubitemid 37484786)
32. Grassetto G, Fornasiero A, Bonciarelli G, Banti E, Rampin L, Marzola MG et al. Additional value of FDG-PET/CT in management of "Solitary" liver metastases: Preliminary Results of a Prospective Multicenter Study. Mol Imaging Biol 2010;12:139-44.
33. Selzner M, Hany T, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004;240:135-9.
34. Matsuo M, Miwa K, Shinoda J, Kako N, Nishibori H, Sakurai K, Yano H et al. Target definition by C11-Methionine-PET for the radiotherapy of brain metastases. Int J Rad Oncol Biol Phys 2009;74:714-22.
35. Horky LL, Hsia EM, Weiss SE, Drappatz J, Gerbaudo VH. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neuroocol 2011;103:137-46.
36. Bergström M, Collins VP, Ehrin E, Ericson K, Eriksson L, Greitz T et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 1983;7:1062-6. (Pubitemid 14246648)
37. Ogawa T, Kanno I, Shishido F, Inugami A, Higano S, Fujita H et al. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 1991;21:198-202.
38. Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergström M et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol 1989;30:225-32. (Pubitemid 19152548)
39. Braun V, Dempf S, Weller R, Reske SN, Schachenmayr W, Richter HP. Cranial neuronavigation with direct integration of (11) C methionine positron emission tomography (PET) data - results of a pilot study in 32 surgical cases. Acta Neurochir (Wien) 2002;144:777-82. (Pubitemid 34985271)
40. Orgera G, Monfardini L, Della Vigna P, Zhang L, Bonomo G, Arnone P et al. High-intensity focused ultrasound (HIFU) in patients with solid malignancies: evaluation of feasibility, local tumour response and clinical results. Radiol Med 2011;116:734-48.
41. Thomas JM, Redding WH, Sloane JP. The spread of breast cancer: importance of the intrathoracic lymphatic route and its relevance to treatment. Br J Cancer 1979;40:540-7. (Pubitemid 10190208)
42. De Weerdt S, Noppen M, Everaert H, Vincken W. Positron emission tomography scintigraphy after thoracoscopic talcage. Respiration 2004;71:284. (Pubitemid 38608347)
43. Bronstein Y, Tummala S, Rohren E. F-18 FDG PET/CT for detection of malignant involvement of peripheral nerves. Case Series and Literature Review. Clin Nucl Med 2011;36:96-100.
44. Ahmad A, Barrington S, Maisey M, Rubens RD. Use of positron emission tomography in evaluation of brachial pleoxopathy in breast cancer patients. Br J Cancer 1999;79:478-82. (Pubitemid 29046222)
45. Gwak HS, Youn SM, Chang U, Lee DH, Cheon GJ, Rhee CH et al. Usefulness of 18F-Fluorodeoxyglucose PET for radiosurgery planning and response monitoring in patients with recurrent spinal metastasis. Minim Invas Neurosurg 2006;49:127-34. (Pubitemid 44140248)
46. Mortazavi-Jehanno N, Giraudet A-L, Champion L, Lerebours F, Le Stanc E, Edeline V et al. Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2012;39:450-60.
47. Ishiwata K, Ido T, Mejia AA, Ichihashi M, Mishima Y. Synthesis and radiation dosimetry of 4-Boron-2-(18F)fluoro-D,L-phenylalanine: a target compound for PET and boron neutron capture therapy. Applied Radiation and Isotopes 1991;42:325-8.
48. Ishiwata K, Shiono M, Kubota K, Yoshino K, Hatazawa J, Ido T et al. A unique in vivo assessment of 4-[10B]boron-L-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-boron-2[18F]fluoro-L-phenylalanine. Melanoma Res 1992;2:171-9.
49. Evangelista L, Jori G, Martini D, Sotti G. Boron neutron capture therapy and 18F-labelled borophenylalanine positron emission tomography: a critical and clinical overview of the literature. Applied Radiation and Isotopes 2013;74:91-101.
50. Yanagie H, Furuya Y, Taniike K, Kumada H, Nakamura T, Horiguchi H et al. Planning of Neutron Capture Therapy for local recurrenced breast cancer according to estimation of boron uptake in tumour by F-BPA Positron Emission Tomography 15th International Congress on Neutron Capture Therapy Program & Abstract Abstract 22.
51. Kawada K, Murakami K, Sato T, Kojjma Y, Ebi H, Mukai H et al. Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. Jpn J Clin Oncol 2007;37:44-8. (Pubitemid 47090722)
52. Cervino AR, Burei M, Mansi L, Evangelista L. Molecular pathways and molecular imaging in breast cancer: an update. Nucl Med Biol 2013 [Epub ahead of print].
53. Mir LM. Terapeutic perpsectives of in vivo cell electropermeabilization. Bioelectrochemestry 2000;53:1-10.
54. Mir LM, Orlowski S. Mechanisms of elettrochemotherapy. Adv Drug Del REv 1999;35:107-18.
55. Belehradek M DC, Luboinski B, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM. Elettrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer 1993;72:3694-700. (Pubitemid 24000606)
56. Campana LG, Mocellin S, Basso M, Puccetti O, De Salco GL, Chiarion-Sileni V et al. Bleomycin-based elettrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol 2009;29:371-87.
57. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M et al. Elettrochemotherapy, an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Elettrochemotherapy) study. EJC Supplements 2006;4:3-13. (Pubitemid 44755131)
58. Curatolo P, Quaglino P, Marenco F, Mancini M, Nardo T, Mortera C et al. Elettrochemotherapy in the treatment of kaposi sarcoma cutanous lesions: A two-center prospective phase II trial. Ann Surg Oncol 2012;19:192-8.
59. Matthiessen LW, Chalmers RL, Sainsbury DC, Veeramani S, Kessell G, Humphreys AC et al. Management of cutaneous metastases using elettrochemotherapy. Acta Oncol 2011;50:621-9.
60. Whelan MC, Larkin JO, Collins CG, Cashman J, Breathnach O, Soden DM et al. Effective treatment of an extensive recurrent breast cancer which was refractory to multimodality therapy by multiple applications of elettrochemotherapy. EJC Supplements 2006;4:32-4. (Pubitemid 44666528)
61. Matthiessen LW, Johannesen HH, Hendel HW, Moss T, Kamby C, Gehl J. Electrochemotherapy for large cutaneous recurrence of breast cancer: A phase II clinical trial. Acta Oncol 2012;51:713-21.
62. Wichmann Matthiessen L, Hjorth Johannesen H, Westergren Hendel H, Moss T, Kamby C, Gehl J. Elettrochemotherapy for large cutaneous recurrence of breast cancer: a phase II clinical trial. Acta Oncologica 2012;51:713-21.
63. No listed authors. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA 1994;271:1587-92.
64. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 1994;271:1593-7. (Pubitemid 24155619)